Nutritional supplements meant to slow the progression of age-related macular degeneration (AMD) may actually accelerate the disease in people with certain genotypes, according to research recently presented at the American Society of Retina Specialists annual meeting.
According to research recently presented at the American Society of Retina Specialists annual meeting, focal or grid laser treatment that coincides with the initiation of intravitreal ranibizumab for the treatment of diabetic macular edema (DME) shows results no better than when laser treatment is deferred for 24 weeks or more.
The National Institutes of Health recently awarded a $215,000 Small Business Technology Transfer Grant to Oraya Therapeutics to investigate how its therapy and gold nanoparticles affect the treatment of wet age-related macular degeneration (AMD).
I want to thank the Macular Pigment Research Group (MPRG), Waterford, Ireland for responding to my assertion that mesozeaxanthin (MZ) in supplement form, even if it was scientifically possible to study alone as a supplement, has not proven as of yet to be necessary to build central foveal macular pigment, improve cone visual function, or uniquely protect the retina from age-related macular degeneration (AMD).
Using human stem cells, researchers at Johns Hopkins have created a three-dimensional complement of human retinal tissue with functioning photoreceptor cells.
We read with interest, and some surprise, Dr. Stuart Richer’s article in Optometry Times entitled “The third carotenoid-mesozeaxanthin (Z-RS) and who needs to consume it.” In this article, Dr. Richer concludes that “simple proclamations...are misleading,” and we concur with his conclusion in this regard
A study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
Gulden Ophthalmics recently introduced Rowe OCT Model Eye, a solid-state tissue phantom that is used by clamping it to an instrument and initiating an OCT test.
Our profession has had to fight for the privilege of caring for our patients with ocular disease. With optometry as a legislated profession, these battles have occurred in every state and, as a result, optometric practice acts vary widely. Ophthalmology does not have to endure such travails. Ophthalmologists can do pretty much whatever is in their purview, as is their right.
A 26-year-old man from Qingdao, China suffered a retinal detachment after using his smartphone non-stop, according to Qingdao Daily.
SECO International has a nearly 100-year history of providing optometric meetings of the highest caliber. SECO 2014 was no different. Lectures by our most esteemed colleagues were plentiful, and the knowledge base which was available to attendees was impactful. The exhibit hall provided the opportunity to demo many of the new technologies mentioned in the lectures. One such piece of equipment was AdaptDx by MacuLogix.
A 56 year-old male patient came into the clinic recently for a second opinion concerning a previous injury to his right eye. A high-powered commercial laser in a physics laboratory was the source of the injury in 2005.
VMA is an OCT finding. Once the adhesion progresses to abnormalities in the retina and becomes symptomatic, some patients become candidates for Jetrea treatment. Careful selection of symptomatic patients with focal areas of adhesion and/or small holes have produced the best post-injection results. I look forward to offering Jetrea treatment to more of my patients.
Joan Hansen, OD, shares her take from “Retina Mysteries Revealed” at the 90th annual SECO International meeting.
Jetrea to launch week of January 14, says ThromboGenics
